FACS Analysis of Chemokine Receptor Expression on Ex Vivo Expanded Hematopoietic Cells
| Cell Type . | CXCR4 . | CCR5 . | CCR2b . |
|---|---|---|---|
| BFU-E derived | — | — | 67 ± 7 |
| CFU-Meg derived | 80 ± 12 | 31 ± 4 | — |
| CFU-GM derived | 64 ± 13 | 44 ± 17 | — |
| Erythrocytes* | — | — | — |
| Platelets* | 87 ± 6 | — | — |
| Cell Type . | CXCR4 . | CCR5 . | CCR2b . |
|---|---|---|---|
| BFU-E derived | — | — | 67 ± 7 |
| CFU-Meg derived | 80 ± 12 | 31 ± 4 | — |
| CFU-GM derived | 64 ± 13 | 44 ± 17 | — |
| Erythrocytes* | — | — | — |
| Platelets* | 87 ± 6 | — | — |
CD34+ BMMNC were obtained from at least 3 different healthy donors and serum-free expanded in liquid cultures as described in Materials and Methods. Gates were set so that less than 5% of cells in the negative isotype control were in the positive gate. Data are presented as the mean percentage of positive cells plus or minus the standard deviation.
Abbreviation: —, means less than or equal to isotype-matched negative control.
Primary hematopoietic material, not ex vivo expanded.